4 Comments

Thanks, Jonathan.

I'd like to reach out to you.

Can you send a contact to howard.wolinsky@gmail.com

Howard

Expand full comment

Hi Howard,

I was a prostate pathologist for 20 years (first external urologic fellow at Johns Hopkins with Jonathan Epstein and it was obvious that we were diagnosing way too many prostate cancers in men who were harmed by their diagnosis and subsequent treatments. PSAchosis is a real thing. I wrote a long detailed letter to the editors of Urology and Urological Oncology offering “prostatic tubular neoplasia” as a more appropriate diagnosis than “cancer” for Gleason score 3+3 lesions but they wouldn’t publish.

Screening programs for PSA, those very same one promoted by pharm companies, were a veritable public health disaster, but the fee-for-procedure medical-industrial complex weren’t quite aligned. Urologists are surgeons and surgeon like to surge. It’s a certain orientation towards life. Go with old soles to a cobbler and they will offer new soles; go to a shoe store and they will offer new shoes; go to a minister and offer salvation.

Oh the stories I could tell . . .

Jonathan Oppenheimer, MD

Expand full comment

Thanks, Anthony.

I have to say the pressure was on from The Notorious RP to act.

But this is a slow-growing cancer for most. So what's the hurry?

I did my legwork. I found where the bodies were buried.

I made my choice.

Are you coming to the Dr. Scholz program on Jan. 30 at 8 pm Eastern?

Dr. Mark Scholz, a pioneer in recommending active surveillance and avoiding the risks of transrectal biopsies, will be featured in a AnCan webinar 8-9:30 p.m. Eastern Jan. 30 .

The program is entitled, "Invasion of the Prostate Snatchers: 13 years later. An evening with Dr. Mark Scholz." To register, click here: https://bit.ly/3VL1aiP

Scholz gave me support when there was none for AS.

Howard

Expand full comment

I read you story "The Notorious Dr. R. P. with interest. Good on you for taking the time to review the evidence. So many men are defaulting to surgery for low risk prostate cancer without being offered the menu of treatment options.

Expand full comment